Pfizer paid Cellectis $80M upfront plus a 10% equity stake (~$31M) and up to $185M per Pfizer-selected target in milestones across 15 Pfizer-chosen and 4 jointly-developed CAR-T targets. Strategically transformative—Pfizer's largest 2014 immuno-oncology entry and the foundation for what later became Allogene Therapeutics.
Key facts
AnnouncedJun 18, 2014
ClosedJun 18, 2014
Deal value$2.9B
Deal typeCo-Development
Therapeutic areaHematologic malignancies and solid tumors
IndicationsHematologic malignancies and solid tumors
Key assetsAllogeneic CAR-T cell therapies against 27 oncology targets
MechanismTALEN gene-edited allogeneic chimeric antigen receptor T cells